GF Fund Management’s Acrivon Therapeutics ACRV Stock Holding History

GF Fund Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-650	Closed	-$1.18K	–	645
2025 Q3	$1.18K	Sell	650 -122	-16%	-$171	﹤0.01%	628
2025 Q2	$919	Hold	772	–	–	﹤0.01%	654
2025 Q1	$1.57K	Buy	772 +118	+18%	+$635	﹤0.01%	655
2024 Q4	$3.94K	Buy	+654	New	+$4.75K	﹤0.01%	619

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

GF Fund Management's ACRV Position: Q4 2025 in Review

GF Fund Management sold out of Acrivon Therapeutics (ACRV) in Q4 2025, closing a stake of 650 shares — an estimated $1.18K sold.

GF Fund Management first reported a position in ACRV in Q4 2024 and held it in 4 quarters. The position peaked at $3.94K in Q4 2024. 48 funds tracked by Wall St. Rank hold ACRV as of Q4 2025.

GF Fund Management reported no remaining Acrivon Therapeutics position as of Q4 2025 after selling out during the quarter.
GF Fund Management sold 650 Acrivon Therapeutics shares in Q4 2025, an estimated $1.18K.
GF Fund Management first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 4 quarters.
GF Fund Management's Acrivon Therapeutics position peaked at $3.94K in Q4 2024.
48 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.